trending Market Intelligence /marketintelligence/en/news-insights/trending/_KtH18tJZsgbB98U9DYSxw2 content esgSubNav
In This List

Flexion Therapeutics appoints chief medical officer amid buyout rumors

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Flexion Therapeutics appoints chief medical officer amid buyout rumors

Flexion Therapeutics co-founder Neil Bodick is transitioning to the position of chief scientific officer to make room for the appointment of Yamo Deniz.

Deniz will take over Bodick's duties as the chief medical officer of the company. He joins Flexion from Sanofi Genzyme where he served as vice president and head of global medical affairs for rare diseases.

The move comes amid rumors that the companies are in talks about a potential merger, the Boston Business Journal writes. Sanofi Genzyme is the specialty care global business unit of Sanofi.

Flexion is awaiting U.S. FDA approval for its Zilretta treatment in osteoarthritis of the knee.